Study Links Lithium Deficiency to Alzheimer’s Disease, Suggests New Treatment Approach
By
highfrequency
Kettled twice. Extra chewy, extra trustworthy.
Summary
A new study suggests that lithium deficiency could be a cause of Alzheimer’s disease, offering a potential therapeutic approach. Researchers found that lithium compounds can reverse disease symptoms in mice, raising hopes for broader treatment options beyond targeting amyloid beta or tau proteins.
Key quotes
· 3 pulled“The idea that lithium deficiency could be a cause of Alzheimer’s disease is new and suggests a different therapeutic approach.”
“The study raises hopes that researchers could one day use lithium to treat the disease in its entirety rather than focusing on a single facet such as amyloid beta or tau.”
“One of the main discoveries in the study is that as amyloid beta begins to form, lithium loss occurs.”
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
